Germany · Delayed Price · Currency is EUR Transgene Statistics
Total Valuation
Transgene has a market cap or net worth of EUR 132.39 million. The enterprise value is 146.69 million.
| Market Cap | 132.39M |
| Enterprise Value | 146.69M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 132.39M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +30.91% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 69.63% |
| Owned by Institutions (%) | 0.05% |
| Float | 35.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.48 |
| PB Ratio | -36.74 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.99 |
| EV / Sales | 19.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.04 |
Financial Position
The company has a current ratio of 0.54
| Current Ratio | 0.54 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.28 |
| Interest Coverage | -17.59 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -49.35% |
| Return on Invested Capital (ROIC) | -71.16% |
| Return on Capital Employed (ROCE) | -4,406.33% |
| Revenue Per Employee | 51,531 |
| Profits Per Employee | -250,211 |
| Employee Count | 144 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.95% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +42.95% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 35.01 |
| Average Volume (20 Days) | 1,511 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Transgene had revenue of EUR 7.58 million and -36.78 million in losses. Loss per share was -0.28.
| Revenue | 7.58M |
| Gross Profit | -29.19M |
| Operating Income | -36.22M |
| Pretax Income | -36.78M |
| Net Income | -36.78M |
| EBITDA | -34.90M |
| EBIT | -36.22M |
| Loss Per Share | -0.28 |
Balance Sheet
The company has 16.77 million in cash and 31.07 million in debt, giving a net cash position of -14.29 million.
| Cash & Cash Equivalents | 16.77M |
| Total Debt | 31.07M |
| Net Cash | -14.29M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -3.60M |
| Book Value Per Share | -0.03 |
| Working Capital | -18.45M |
Cash Flow
In the last 12 months, operating cash flow was -22.96 million and capital expenditures -1.34 million, giving a free cash flow of -24.30 million.
| Operating Cash Flow | -22.96M |
| Capital Expenditures | -1.34M |
| Free Cash Flow | -24.30M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -478.15% |
| Pretax Margin | -485.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Transgene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.91% |
| Shareholder Yield | -30.91% |
| Earnings Yield | -27.78% |
| FCF Yield | -18.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Transgene has an Altman Z-Score of -3.81 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.81 |
| Piotroski F-Score | 4 |